Gumusel, M.Ozdemir, M.Mevlitoglu, I.Bodur, S.2020-03-262020-03-2620110926-99591468-3083https://dx.doi.org/10.1111/j.1468-3083.2010.03927.xhttps://hdl.handle.net/20.500.12395/26473Background Treatment of psoriatic nail is difficult. Objective The aim of this study was to evaluate and compare the efficacy and safety of methotrexate and cyclosporine in psoriatic nail. Methods Thirty-seven psoriatic patients with nail involvement were randomized to treatment with methotrexate (initial dose, 15 mg per week) or cyclosporine (initial dose, 5 mg per kg of bodyweight per day) for 24 weeks. The primary outcome was the Nail Psoriasis Severity Index (NAPSI). The Psoriasis Area and Severity Index (PASI), doctor and patient global score were also measured. The scores were determined by a blinded observer. Results Seventeen patients completed the study in each group. The mean percentages of reduction of the NAPSI score after methotrexate and cyclosporine treatments were 43.3% and 37.2%, respectively. No significant differences between the treatment groups was found for in the NAPSI, PASI, physician's and patient's global score at the end of the study period. The methotrexate group showed a significant improvement in nail matrix scores and the cyclosporine group in nail bed score. Conclusion Moderate effectiveness on psoriatic nail was found in the two treatment agents and there were no significant differences in efficacy between the groups. A significant improvement was detected in methotrexate group for the nail matrix findings, and in cyclosporine group for the nail bed findings.en10.1111/j.1468-3083.2010.03927.xinfo:eu-repo/semantics/closedAccesscyclosporinemethotrexateNAPSIpsoriatic nailArticle2591080108421118309Q1WOS:000293556400013Q1